Skip to main content
SPT logo

SPT — Investor Relations & Filings

Ticker · 1789 ISIN · TW0001789006 TW Manufacturing
Open in API
Filings indexed 2,236 across all filing types
Latest filing 2023-02-06 Director's Dealing
Country TW Taiwan
Listing TW 1789

About SPT

https://www.scinopharm.com/tw

ScinoPharm Taiwan, Ltd. is a global provider of high-quality Active Pharmaceutical Ingredients (APIs) and comprehensive Contract Development and Manufacturing Organization (CDMO) services. The company specializes in process research, development, and cGMP production, maintaining a leadership position in oncology APIs. Its portfolio covers therapeutic areas including cancer, hematology, metabolic disorders, and central nervous system diseases. ScinoPharm offers one-stop solutions encompassing peptide synthesis, API process development, and the manufacturing of sterile injectables and complex generics. The company is distinguished by its expertise in high-barrier pharmaceutical technologies and adherence to stringent international regulatory standards, such as the U.S. FDA. Serving both generic and innovative drug sectors, it leverages advanced R&D and integrated manufacturing to support global healthcare markets.

Recent filings

Filing Released Lang Actions
112年01月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document contains detailed tables listing shareholdings of company insiders, including directors, chairman, general manager, and their related parties. It shows the number of shares held, changes in holdings, and other related information. This type of document is typically a disclosure of insider share transactions or holdings by directors and executives. There is no indication of financial results, earnings, management discussion, or other report types. The document is not a report publication announcement or a certification. Therefore, it fits the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades).
2023-02-06 Chinese
112年01月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings and pledges by insiders and related parties of Taiwan Shenlong Co., Ltd. It lists share counts for directors, supervisors, and senior management, including pledged shares and ownership percentages. There is no indication of financial statements, management discussion, earnings data, or meeting materials. The content is focused on insider shareholdings and related disclosures. This matches the definition of Director's Dealing (DIRS), which covers reports of personal share transactions or holdings by company directors and executives. The document length is about 5,546 characters, which is sufficient for a detailed insider shareholding report rather than a brief announcement. Therefore, the appropriate classification is DIRS with high confidence.
2023-02-06 Chinese
112年01月法人說明會簡報 — 178920230110E001.pdf
Investor Presentation Classification · 95% confidence The document is titled 'ScinoPharm Investor Conference January, 2023' and contains detailed company overview, business updates, financial performance data including consolidated income statement, balance sheet, and cash flow statement for 3Q 2022, as well as sales distribution and pipeline information. It includes forward-looking statements and detailed operational and financial data. The content is structured as a presentation for investors, focusing on financials, strategy, and market position. There is no indication that this is a full annual or quarterly report filing, nor is it a transcript or regulatory filing. The presence of slides, agenda, and detailed business and financial updates aligns with an Investor Presentation (IP). The document length is substantial (over 14,000 characters), indicating it is the full presentation, not just an announcement or summary. Therefore, the most appropriate classification is Investor Presentation (IP).
2023-01-11 Chinese
112年01月法人說明會簡報 — 178920230110M001.pdf
Investor Presentation Classification · 95% confidence The document is a detailed presentation from ScinoPharm Co., Ltd. dated January 2023, containing company overview, business status, financial performance including consolidated income statement, balance sheet, and cash flow statement for the first three quarters of 2022, as well as product pipeline and market information. It includes financial data and analysis but is structured as a presentation rather than a formal report like an annual or interim report. The presence of slides, charts, and business outlook indicates it is an investor-focused presentation. There is no indication that this is an official annual report (10-K), quarterly/interim report (IR), or earnings release (ER). It is not a regulatory filing or announcement. Therefore, the best fit is Investor Presentation (IP). The document length (over 11,000 characters) and detailed financial data support this classification with high confidence.
2023-01-11 Chinese
112年01月法人說明會簡報
Investor Presentation Classification · 95% confidence The document is a listing from a public information observation station showing details about a company's investor presentation event, including date, time, location, and links to presentation materials (PDF files). It mentions a company participating in a healthcare conference and providing explanations on previously disclosed financial data and operational overview. The document does not contain actual financial statements or detailed financial analysis but rather information about a presentation event and related materials. Therefore, it fits the category of an Investor Presentation (IP). The document length is short and it is not merely an announcement of a report publication, but includes presentation content links, supporting the classification as IP rather than RPA or RNS.
2023-01-11 Chinese
本公司受邀參加J.P. Morgan舉辦之2023 Healthcare Conference
Investor Presentation Classification · 90% confidence The document is a brief announcement about the company's participation in the J.P. Morgan 2023 Healthcare Conference, including the date, time, and location of the investor presentation. It mentions that the company will explain previously disclosed financial figures and operational overview. The document is short (774 characters) and does not contain actual financial statements or detailed analysis. It serves as a notice of an upcoming investor presentation event rather than the presentation itself or a detailed report. Therefore, it fits the category of Investor Presentation (IP).
2023-01-10 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.